According to research reviewed by Gram, most common osteoporosis medicines were not linked to higher rates of heart attack, stroke, or irregular heartbeat in a 2026 UK study of 306,457 women. Zoledronic acid users had about 1.9 times the rate of irregular heartbeat, and ibandronate users had about 1.5 times the rate of heart attack, though these findings rested on small numbers.
Osteoporosis medicines help keep bones strong, but patients and doctors also want to know how they affect the heart. According to research reviewed by Gram, a large UK study followed 306,457 women aged 40 to 89 who had no history of heart disease. The women who took most common osteoporosis medicines had heart attack, stroke, and irregular heartbeat rates similar to women taking only vitamin D. Two exceptions stood out. Zoledronic acid users had a higher rate of atrial fibrillation, a irregular heartbeat, and ibandronate users had a higher rate of heart attacks. However, these findings were based on small numbers of people, so the researchers could not confirm the medicines were the cause. Larger studies are needed before firm conclusions can be drawn.
Key Statistics
A 2026 cohort study of 306,457 women in UK primary care records found that stroke rates were similar across all osteoporosis treatments compared to vitamin D users.
In a 2026 UK cohort study, women taking zoledronic acid had about 1.87 times the rate of atrial fibrillation (irregular heartbeat) compared to vitamin D users, based on only 13 cases.
A 2026 UK cohort study of 306,457 women found that ibandronate users had about 1.50 times the rate of heart attack compared to vitamin D users, based on 63 cases.
The Quick Take
- What they studied: The researchers wanted to know whether common osteoporosis medicines, which treat weak bones, are linked to a higher chance of heart problems such as irregular heartbeat, heart attack, or stroke in women.
- Who participated: The study used anonymous health records from UK general practices. It included 226,484 women taking an osteoporosis medicine and 79,973 women taking only vitamin D, for a total of 306,457 women. All were aged 40 to 89 and had no earlier heart disease.
- Key finding: Most osteoporosis medicines were not linked to higher rates of heart problems. Zoledronic acid users had about 1.9 times the rate of irregular heartbeat (atrial fibrillation) compared to vitamin D users, and ibandronate users had about 1.5 times the rate of heart attack. These results were based on only 13 and 63 cases, so the uncertainty is high.
- What it means for you: If you take an osteoporosis medicine, this study does not suggest you should stop. Discuss any heart concerns with your doctor, especially if you have a personal or family history of heart problems. Your doctor can weigh the bone benefits against any possible heart risks for your situation.
The Research Details
This was a cohort study, which means researchers followed a group of people over time to see who developed certain health problems. The team used records from the Clinical Practice Research Datalink, a large database of UK general practice visits, and linked them to hospital records. The records covered 2000 to 2020.
The researchers built two groups. The first group, called the treated group, included women who had just started taking one of nine osteoporosis medicines. These included several bisphosphonates, which are bone-strengthening drugs, along with denosumab, raloxifene, teriparatide, and calcitonin. The second group, called the comparison group, included women who were prescribed vitamin D and had an osteoporosis diagnosis or bone monitoring. Vitamin D was used as a reference point because it is not expected to affect the heart in the same way.
Following each woman from her first prescription until a health event, a major illness, age 90, or the end of her records, the team counted how often irregular heartbeat, heart attack, stroke, and fatal stroke occurred. They then adjusted the numbers for factors such as age and other health conditions to make the groups more comparable.
The study used a very large dataset, which is a strength. It also used a reference group and statistical adjustments to account for differences between the women. However, the researchers themselves noted that many of the specific heart outcomes were rare, so estimates for individual medicines are imprecise. Health records can also miss some diagnoses or medication use, and the study cannot fully rule out other explanations for the differences seen.
What the Results Show
Across the study, researchers recorded 4,313 cases of irregular heartbeat (atrial fibrillation), 7,312 strokes, and 3,846 heart attacks. For most osteoporosis medicines, the rates of these events were similar to those in the vitamin D group. This suggests that for most women, these medicines did not noticeably change their heart risk in this dataset.
The clearest exception was zoledronic acid, a medicine given by IV infusion. Among its users, 13 women developed irregular heartbeat. After adjustments, their rate was about 1.87 times the rate in the vitamin D group, with a range of 1.08 to 3.24. Because the range is wide and the number of cases is small, this finding is uncertain. It may be a real effect, a chance result, or influenced by other factors.
Another difference appeared for ibandronate, a bisphosphonate taken as a tablet or IV infusion. Sixty-three ibandronate users had a heart attack, giving a rate about 1.50 times the vitamin D group, with a range of 1.16 to 1.95. The researchers described this increase as somewhat notable but still based on limited data. Other medicines showed no clear difference in heart attack rates.
Stroke rates were similar across all osteoporosis treatments compared to vitamin D, and fatal stroke showed no clear differences for any medicine. This is reassuring, since stroke is a serious cause of disability. The similarity across different bisphosphonates also suggests that these drug types do not differ greatly in their stroke risk in this data.
The researchers also noted that the increased rates for zoledronic acid and ibandronate might be explained by other factors. Women who need these medicines may have had prior fractures or mineral imbalances in the blood, and those factors can affect heart health. The study could not separate these influences from the medicines themselves.
Bisphosphonates have been studied for several years, and many large studies have found no strong link to heart problems for most of them. Some earlier reports raised questions about irregular heartbeat with zoledronic acid, and this study adds to that discussion without settling it. The heart attack finding for ibandronate is less commonly reported, so it needs further confirmation from other datasets.
The biggest limitation is the small number of events for zoledronic acid and ibandronate. Small numbers make results less stable, and the wide ranges show how much uncertainty remains. The study also could not determine whether the medicines caused the extra events or whether the women who received them had higher risk to begin with. Factors such as fracture history, blood mineral levels, and lifestyle were not fully measured. Because the study relied on medical records, some diagnoses may have been missed or recorded inaccurately. Finally, the study included only women, so the results may not apply to men.
The Bottom Line
Based on this study, the evidence supports the general safety of most osteoporosis medicines regarding heart problems in women, with moderate confidence. The results for zoledronic acid and ibandronate are less certain and should be treated as a reason for more research and careful discussion with a doctor, not as proof of harm. Patients should not stop prescribed medicines based on this study alone.
Women who take or are considering osteoporosis medicines, and the clinicians who prescribe them, should find this useful. People with existing heart disease were excluded from the study, so people with heart conditions should talk to their doctor before drawing conclusions. Men, and women outside the age range studied, were not included, so the findings may not apply to them.
Bone-strengthening effects of osteoporosis medicines usually develop over months to years, and fracture risk reductions are typically seen over one to three years of treatment. Any heart-related effects, if they exist, would also take time to show up. A doctor can review your heart health and bone health at regular checkups.
Frequently Asked Questions
Do osteoporosis medicines increase the risk of heart attack in women?
A 2026 UK study of 306,457 women found most osteoporosis medicines were not linked to higher heart attack rates. Ibandronate users had about 1.5 times the rate compared to vitamin D users, but this was based on 63 cases and needs more research.
Is zoledronic acid linked to irregular heartbeat?
A UK cohort study found zoledronic acid users had about 1.87 times the rate of atrial fibrillation compared to vitamin D users. The finding came from only 13 cases, so the researchers said more large studies are needed before drawing firm conclusions.
Do osteoporosis drugs raise stroke risk?
In a large UK study of 306,457 women, stroke rates were similar across all osteoporosis treatments compared to vitamin D. Fatal stroke rates also showed no clear differences between medicines, according to research reviewed by Gram.
Should I stop my osteoporosis medicine because of heart concerns?
Research reviewed by Gram does not support stopping prescribed osteoporosis medicine based on this study alone. Talk with your doctor about your heart health, bone fracture risk, and any symptoms, so you can weigh benefits and risks for your situation.
Want to Apply This Research?
- Log your osteoporosis medicine name, dose, and the date you started it. Record your resting heart rate and blood pressure weekly, and note any episodes of racing, pounding, or irregular heartbeat, along with how long they lasted.
- Set a reminder to take your osteoporosis medicine as prescribed, and add a prompt to write down any new chest discomfort, palpitations, or shortness of breath. Share the log with your doctor at each appointment so they can review your heart and bone health together.
- Review your logged heart rate and symptom notes monthly, and bring a summary to yearly checkups. Ask your doctor whether heart health screening is appropriate for you, especially if you have risk factors such as high blood pressure, diabetes, or a family history of heart disease.
This article summarizes a single observational study and is for general information only. It is not medical advice. The study found associations in small subgroups that may be due to chance or other factors. Do not start, stop, or change any medicine without speaking to your doctor or pharmacist, who can review your personal medical history.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.